EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

BRCA1‐associated‐protein‐1 inactivated melanocytic tumours: characterisation of the clinicopathological spectrum and immunohistochemical expression pattern of preferentially expressed antigen in melanoma

Yitong Xu, Alejandro A Gru iD, Thomas Brenn iD, Katharina Wiedemeyer iD

Histopathology · 2025

DOI: 10.1111/his.15318 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Histopathology, 2025. Verfasst von Yitong Xu und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology and Laboratory Medicine, University of Calgary, Calgary, AB, Canada. Hauptthemen laut MEDLINE: Antigens, Neoplasm, Immunohistochemistry, Melanocytes, Skin Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Calgary.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

BRCA1‐associaed protein‐1 (BAP1) inactivated tumours (BIMT) are rare melanocytic tumours that may be mistaken for Spitz tumours or melanoma. They occur sporadically or in association with the BAP1 tumour predisposition syndrome (BAP1–TPDS), which may be complicated by uveal or cutaneous melanoma, mesothelioma, basal cell carcinoma and renal cell carcinoma. The aim of this study was to characterise the clinicopathological features and the immunohistochemical expression pattern of preferentially expressed antigen in melanoma (PRAME) of BIMT in a large patient cohort. Methods and results Ethical approval was obtained, haematoxylin and eosin‐stained slides were reviewed, PRAME immunohistochemistry was performed and clinical follow‐up was obtained from patient records. Sixty‐five BIMT from 38 patients (F:M = 4.4:1) were identified. BIMT were typically located on the trunk and head and neck (median size = 0.5 cm). Seven patients with BAP1–TPDS (range = 16–66 years, median = 25) had multiple BIMT (median = 5), while sporadic BIMT were solitary (median patient age = 39 years). One of seven patients with BAP1–TPDS developed additional malignancies (mesothelioma and cutaneous spindle cell melanoma) and died of complications of mesothelioma. All other patients are alive without recurrence of BIMT (median follow‐up = 42 months). BIMT presented as intradermal, nodular aggregates of epithelioid melanocytes with low mitotic activity and moderate to severe cytological atypia in 63% of cases. A background conventional naevus was present in 64%. PRAME immunohistochemistry showed negative or weakly patchy positive staining in all BIMT.

Conclusions

BIMT are more common in a sporadic setting and behave indolently, despite worrying cytological atypia. PRAME immunohistochemistry is a reassuring tool in distinguishing BIMT from melanoma.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antigens, NeoplasmImmunohistochemistryMelanocytesSkin NeoplasmsTumor Suppressor ProteinsAdolescentAdultAgedFemaleMaleMiddle AgedYoung AdultCell ProliferationDermisHumansUbiquitin Thiolesterase

Stichwörter der Autor:innen

BAP1PRAMEatypical Spitzgermline mutationmelanocytic tumourmelanoma

Substanzen

Antigens, NeoplasmBAP1 protein, humanPRAME protein, humanTumor Suppressor ProteinsUbiquitin Thiolesterase

Autor:innen und Institutionen

  • Department of Pathology and Laboratory Medicine, University of Calgary, Calgary, AB, Canada.
  • Department of Pathology, University of Virginia, Charlottesville, VA, USA.
  • Department of Pathology, New York-Presbyterian Hospital/Columbia University Irving Medical Center, New York, USA.
  • Arnie Charbonneau Cancer Institute, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.
  • Department of Pathology, University of Michigan, Ann Arbor, MI, USA.

ORCID-Profile: Alejandro A Gru, Thomas Brenn, Katharina Wiedemeyer

Förderung

  • University of Calgary

Zitieren

APA

Xu, Y., Gru, A. A., Brenn, T., & Wiedemeyer, K. (2025). BRCA1‐associated‐protein‐1 inactivated melanocytic tumours: characterisation of the clinicopathological spectrum and immunohistochemical expression pattern of preferentially expressed antigen in melanoma. Histopathology. https://doi.org/10.1111/his.15318

Vancouver

Xu Y, Gru AA, Brenn T, Wiedemeyer K. BRCA1‐associated‐protein‐1 inactivated melanocytic tumours: characterisation of the clinicopathological spectrum and immunohistochemical expression pattern of preferentially expressed antigen in melanoma. Histopathology. 2025. doi:10.1111/his.15318

BibTeX
@article{Xu2025,
  author = {Xu, Yitong and Gru, Alejandro A and Brenn, Thomas and Wiedemeyer, Katharina},
  title = {BRCA1‐associated‐protein‐1 inactivated melanocytic tumours: characterisation of the clinicopathological spectrum and immunohistochemical expression pattern of preferentially expressed antigen in melanoma},
  journal = {Histopathology},
  year = {2025},
  doi = {10.1111/his.15318}
}
Kostenlos starten →